Literature DB >> 19164931

Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice.

Chantal Zuber1, Gerda Mitteregger, Claudia Pace, Inga Zerr, Hans A Kretzschmar, Stefan Weiss.   

Abstract

We identified the 37kDa/67kDa laminin receptor (LRP/LR) as a cell surface receptor for the cellular prion protein (PrP(c)) and the infectious prion protein (PrP(Sc)). Recently, we showed that anti-LRP/LR antibody W3 cured scrapie infected N2a cells. Here, we demonstrate that W3 delivered by passive immunotransfer into C57BL/6 mice reduced the PrP(Sc) content in the spleen significantly by 66%, demonstrating an impairment of the peripheral PrP(Sc) propagation. In addition, we observed a 1.8-fold increase in survival of anti-LRP/LR antibody W3 treated mice (mean survival of 31 days) compared to preimmune serum treated control animals (mean survival of 17 days). We conclude that the significant effect of anti-LRP/LR antibody W3 on the reduction of peripheral PrP(Sc) propagation might be due to the blockage of the prion receptor LRP/LR which is required, as previously shown in vitro, for PrP(Sc) propagation in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19164931      PMCID: PMC2634594          DOI: 10.4161/pri.1.3.5273

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  33 in total

1.  Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor.

Authors:  C Hundt; J M Peyrin; S Haïk; S Gauczynski; C Leucht; R Rieger; M L Riley; J P Deslys; D Dormont; C I Lasmézas; S Weiss
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 2.  Interaction of prion proteins with cell surface receptors, molecular chaperones, and other molecules.

Authors:  S Gauczynski; C Hundt; C Leucht; S Weiss
Journal:  Adv Protein Chem       Date:  2001

Review 3.  Towards cellular receptors for prions.

Authors:  Kil Sun Lee; Rafael Linden; Marco Antônio M Prado; Ricardo R Brentani; Vilma R Martins
Journal:  Rev Med Virol       Date:  2003 Nov-Dec       Impact factor: 6.989

4.  Postexposure prophylaxis against prion disease with a stimulator of innate immunity.

Authors:  Shneh Sethi; Grayson Lipford; Hermann Wagner; Hans Kretzschmar
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

5.  Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: Implications for therapeutic use in prion diseases.

Authors:  Séverine Padiolleau-Lefevre; Coralie Alexandrenne; Fatima Dkhissi; Gilles Clement; Sosthène Essono; Céline Blache; Jean-Yves Couraud; Anne Wijkhuisen; Didier Boquet
Journal:  Mol Immunol       Date:  2007-03       Impact factor: 4.407

6.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

Review 7.  Therapeutic approaches to prion diseases.

Authors:  Giacomina Rossi; Mario Salmona; Gianluigi Forloni; Orso Bugiani; Fabrizio Tagliavini
Journal:  Clin Lab Med       Date:  2003-03       Impact factor: 1.935

8.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Evaluation of quinacrine treatment for prion diseases.

Authors:  A Barret; F Tagliavini; G Forloni; C Bate; M Salmona; L Colombo; A De Luigi; L Limido; S Suardi; G Rossi; F Auvré; K T Adjou; N Salès; A Williams; C Lasmézas; J P Deslys
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells.

Authors:  Christoph Leucht; Steve Simoneau; Clémence Rey; Karen Vana; Roman Rieger; Corinne Ida Lasmézas; Stefan Weiss
Journal:  EMBO Rep       Date:  2003-03       Impact factor: 8.807

View more
  6 in total

1.  Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.

Authors:  Claude Carnaud; Véronique Bachy
Journal:  Prion       Date:  2010-04-04       Impact factor: 3.931

Review 2.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

3.  Characterization of the ovine ribosomal protein SA gene and its pseudogenes.

Authors:  Alice Van den Broeke; Mario Van Poucke; Ane Marcos-Carcavilla; Karine Hugot; Hélène Hayes; Maud Bertaud; Alex Van Zeveren; Luc J Peelman
Journal:  BMC Genomics       Date:  2010-03-16       Impact factor: 3.969

4.  Expression and distribution of laminin receptor precursor/laminin receptor in rabbit tissues.

Authors:  Huinuan Wang; Lifeng Yang; Mohammed Kouadir; Rongrong Tan; Wenyu Wu; Huarong Zou; Jin Wang; Sher Hayat Khan; Dongfeng Li; Xiangmei Zhou; Xiaomin Yin; Yunsheng Wang; Deming Zhao
Journal:  J Mol Neurosci       Date:  2013-05-30       Impact factor: 3.444

5.  Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.

Authors:  Saci Iken; Véronique Bachy; Pauline Gourdain; Annick Lim; Sylvie Grégoire; Thomas Chaigneau; Pierre Aucouturier; Claude Carnaud
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

6.  The 37/67 kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67 kDa LR cell surface localization and interaction with the cellular prion protein.

Authors:  Daniela Sarnataro; Anna Pepe; Gennaro Altamura; Imma De Simone; Ada Pesapane; Lucio Nitsch; Nunzia Montuori; Antonio Lavecchia; Chiara Zurzolo
Journal:  Sci Rep       Date:  2016-04-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.